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T2D, which is characterized by high plasma glucose levels and insulin resistance, has become a major medical challenge in the United States and around the world 1, 2 . If untreated, severe and sometimes fatal complications can develop. Most patients rely on pharmacotherapy for hyperglycemic control for the rest of their lives 3, 4 . However, the drugs available currently are not effective in correcting the underlying cause of insulin resistance in peripheral tissues, and patients often become refractory to treatment 3, 4 . Development of new antidiabetic drugs with new mechanisms of action, in particular those targeting the cause of insulin resistance, is important to improve diabetes therapy.
Obesity is one of the most important risk factors of T2D. Excessive accumulation of lipids affects the normal functions of adipose, liver, muscle and pancreatic beta cells, which all contribute to the development of insulin resistance and hyperglycemia [5] [6] [7] [8] . Although exactly how lipid accumulation leads to peripheral insulin resistance is still not fully understood, a number of mechanisms have been proposed, including an increase of intracellular lipid metabolites [9] [10] [11] [12] [13] , inflammation and alterations in plasma cytokine levels [14] [15] [16] [17] [18] [19] [20] . Consistent with an important causal role of ectopic accumulation of lipids in insulin resistance, in a number of nonpharmacological approaches that are effective in reversing T2D conditions, such as aerobic exercise and moderate weight loss [21] [22] [23] , reversal of insulin resistance is highly correlative with a reduction of triglyceride content in the liver 24 . Therefore, reducing ectopic lipid accumulation in the liver or muscles is an appealing strategy for treating T2D.
Mitochondria are at the center of glucose and fatty acid metabolism. Mitochondrial uncouplers, which reduce the proton gradient across the mitochondrial inner membrane, create a futile cycle of glucose and fatty acid oxidation without generating ATP [25] [26] [27] [28] . They are expected to increase lipid oxidation and reduce intracellular lipid content 29, 30 . Transgenic mouse models that express mitochondrial uncoupling proteins in liver or muscle exhibit elevated fatty acid oxidation and reduced intracellular lipid accumulation [31] [32] [33] [34] . They also show substantial resistance to weight gain induced by feeding a high-fat diet (HFD) 31, 33 and are protected from HFD-induced insulin resistance 35, 36 .
The effect of mitochondrial uncoupling on reducing intracellular lipid accumulation prompted us to search for safe mitochondrial uncouplers and evaluate their potential use for T2D treatment. Partial mitochondrial uncoupling can be well tolerated by mammalian cells [37] [38] [39] . Moreover, mitochondrial uncouplers have been used in humans before. The best known chemical mitochondrial uncoupler is 2,4-dinitrophenol (DNP), which was a drug approved for treating obesity in the 1930s 40 . It increases the metabolic rate in humans, leading to effective loss of body fat. However, DNP has a narrow therapeutic index because it causes hyperthermia at high dosages and was withdrawn from the market. The potential effect of DNP in treating T2D in humans was not adequately investigated at the time; however, a recent study has shown that a liver-targeted derivative of DNP promotes hepatic fat oxidation and reduces hepatic steatosis and insulin resistance in HFD-fed and diabetic rats, with a 50-fold increase in the therapeutic index compared to DNP 41 .
Niclosamide (5-chloro-salicyl-(2-chloro-4-nitro) anilide) is an anthelmintic drug approved by the US Food and Drug Administration (FDA) for treating intestinal infections of tapeworms 42, 43 . The mechanism of action of the drug is to uncouple the mitochondria of the parasitic worms [42] [43] [44] , and it has an excellent safety profile 42, 43, 45, 46 . NEN is a salt form of niclosamide that has higher water solubility. The median lethal dose (LD 50 ) of oral NEN in mammals appears to be the same or even higher than that of niclosamide 45, 46 . Long-term oral treatment (ranging from months to over a year) with NEN at high dosages in experimental mammals such as rats and dogs does not show any adverse effects 45, 46 . Encouraged by the excellent safety profile of NEN, we systematically investigated NEN as an oral treatment for T2D.
RESULTS

Properties of NEN in uncoupling mammalian mitochondria
The chemical structure of NEN salt is shown in Figure 1a . The hallmark of mitochondrial uncoupling is the induction of mitochondrial oxygen consumption, even in the presence of F o F 1 ATP synthase inhibitors such as oligomycin 25 . NEN at a concentration of 1 µM induced oxygen consumption of mitochondria isolated from C57BL/6J mouse livers in the presence of oligomycin (Fig. 1b) . Moreover, at the same concentration, NEN markedly increased oxygen consumption in live cells in the presence or absence of oligomycin (Fig. 1c) .
Further analyses showed that NEN started to reduce the mitochondria membrane potential in live cells at concentrations of around 500 nM (Supplementary Fig. 1a ). The effect was readily observed within 30 min (Supplementary Fig. 1b ) and was reversible (Supplementary Fig. 1c ).
The effect of oral NEN on energy metabolism in mice We performed pharmacokinetic and tissue distribution studies in C57BL/6J mice after oral administration of NEN. A gavage of 40 mg kg −1 body weight of NEN led to peak plasma concentrations of ~400-900 ng ml −1 (~1-2.5 µM) (Supplementary Fig. 2a) . The half-life of NEN in these mice was ~1.25 h (Supplementary Fig. 2b) . NEN was distributed primarily to the liver, with relatively high levels of metabolite present in the kidney and low or negligible levels in all other tissues examined (Supplementary Fig. 2c ).
We then examined the metabolic effect of oral NEN in vivo. We fed the mice HFD alone (control) or HFD containing 1,500 p.p.m. NEN (equivalent of ~150 mg per kg body weight per day), a dosage well below a level documented to have no adverse effects in rodents (~25,000 p.p.m. in feed or 1,250 mg per kg body weight per day in rats) 45, 46 and performed indirect calorimetry (IDC) studies. Compared to the controls, mice fed NEN showed a higher energy expenditure rate (Fig. 1d) . In addition, they exhibited a higher oxygen consumption rate (Fig. 1e) , a marginally higher carbon dioxide production rate (Fig. 1f) and a lower respiration quotient (Fig. 1g) , which is indicative of a larger proportion of energy expenditure derived from lipid oxidation. We also analyzed the effects of NEN on body temperature and did not observe any differences between the control and NEN-treated mice (Fig. 1h) .
The effect of oral NEN on diabetic mouse models The effect of oral NEN on energy expenditure and lipid oxidation prompted us to determine the effect of NEN on glycemic control. First we tested whether NEN is efficacious in preventing the development of insulin resistance and hyperglycemia in a HFD-induced diabetic mouse model. We fed C57BL/6J mice either HFD (control) or HFD containing NEN. NEN treatment prevented the elevation of fasting blood glucose and basal plasma insulin concentrations (Fig. 2a,b) . In addition, the mice fed with NEN showed better insulin sensitivity than the controls, as determined by glucose tolerance assays (Fig. 2c) and insulin sensitivity assays (Fig. 2d) . The NEN-treated mice also exhibited slightly lower levels of glycated hemoglobin than the controls (Supplementary Fig. 3a,b) . Consistent with the mitochondrial uncoupling mechanism, which increases the oxidation of pyruvate rather than shunting pyruvate for the formation of lactate, as complex I inhibitors do 47, 48 , mice fed with NEN exhibited lower fasting blood lactate concentrations than the controls (Fig. 2e) . The better glycemic control in the NEN-treated mice correlated with smaller (Fig. 2f) , an effect that was not caused by less food intake or poorer nutrient absorption, as determined by food intake assay ( Supplementary Fig. 3c ), daily fecal weight and fecal triglyceride content analyses ( Supplementary Fig. 3d,e) . We further tested whether oral NEN is effective in reversing hyperglycemia in the mouse model after the condition has been established. We first fed the mice with HFD for 4 months and then either continued with HFD feeding or switched the mice to HFD containing NEN. NEN treatment significantly reduced fasting blood glucose concentrations (Fig. 2g) . Basal plasma insulin concentrations in the NEN-treated mice were also lower compared to controls (Fig. 2h) . In addition, the NEN-fed mice showed better insulin sensitivity than controls (Fig. 2i,j) . Consistently, as compared to control mice, the NEN-fed mice exhibited slightly lower levels of glycated hemoglobin ( Supplementary Fig. 3f,g ).
We further examined whether oral NEN is effective in improving glycemic control in the db/db mouse model, in which mice become obese within 4 weeks and develop severe hyperglycemic symptoms within 8 weeks because of hyperphagia due to a mutation in the leptin receptor gene. At the age of 5 weeks, we randomized db/db mice into two groups: one group fed normal chow (control) and one group fed the same chow but containing 1,500 p.p.m. NEN. Throughout the treatment course, the NEN-treated mice exhibited lower blood glucose concentrations than the controls (Fig. 3a) . In addition, whereas plasma insulin concentrations declined rapidly in the control db/db mice as the disease progressed, probably due to pancreatic beta cell exhaustion 49 ( Fig. 3b) , the course of plasma insulin decline was slowed down significantly in the NEN-treated mice (Fig. 3b) . Consistently, glycated hemoglobin A1c (HbA1c) levels in the NEN-treated mice were more than 2% lower than the levels in controls after the 60-day treatment (4.9 ± 1.0% compared to 7.7 ± 0.9% (mean ± s.d.); Fig. 3c ), indicating markedly better glycemic control in the NEN-treated db/db mice. Because of the rapid deterioration of disease in db/db mice, the average body weight of the controls at day 60 was similar to that at day 30, despite the presence of hyperphagia. Consistent with a slower disease progression, the NEN-treated mice still showed some body weight gain in the same period (Fig. 3d) . There was no significant difference in food intake between the control and the NEN-treated mice (Fig. 3e) .
The effect of oral NEN on the livers of HFD-fed mice To determine the mechanism by which NEN improves glycemic control, we compared the organs and tissues of mice fed either HFD alone or HFD containing NEN. Consistent with the fact that NEN is distributed primarily to the liver after oral treatment ( Supplementary Fig. 2c ), the most striking difference between the two groups of mice was the size and appearance of the liver (Fig. 4a,b) . Other organs, except white adipose, did not show any apparent differences in terms of mass or appearance (data not shown). Histological analyses of the mouse livers showed that although HFD induced massive hepatic steatosis (Fig. 4c) , mice fed NEN-containing HFD showed little intracellular lipid accumulation in the liver (Fig. 4c) , which we confirmed by quantification of the triglyceride content of liver tissues (Fig. 4d) . We then determined whether oral NEN could improve hepatic steatosis after the condition has been established. We first fed the mice HFD for 4 months and then switched to HFD containing NEN. Histological analyses and lipid content quantification showed that NEN treatment correlated with a lower degree of lipid accumulation in the liver, even though the mice were still on the HFD (Fig. 4c,d) .
Hepatic lipid metabolites, such as diacylglycerol (DAG) and ceramide, are important mediators of insulin resistance 50 . Consistently, cytosolic DAG concentrations in livers from NEN-treated mice were significantly lower than those in controls (P < 0.001; Supplementary  Fig. 4a ). However, NEN-treated mice did not show lower hepatic ceramide contents than controls (Supplementary Fig. 4b ). Lowgrade inflammation, particularly in adipose tissue, is an important (i,j) Glucose tolerance assay (i) and insulin sensitivity assay (j) of the mice described in g performed at week 3 of the HFD regimen. n = 7 for all groups. *P < 0.05, **P < 0.01, ***P < 0.001. Statistical significance (P) was determined by Student's t test. All error bars, s.d.
npg contributing factor to insulin resistance. We analyzed the expression of the proinflammatory cytokine genes Tnfa and Il6 in hepatic and adipose tissues and found no difference between the mice treated with HFD and those treated with HFD containing NEN ( Supplementary  Fig. 4c,d ). These results suggest that DAG, but not ceramide or inflammation, might be important in mediating the effects of NEN.
We compared the ultrastructures of hepatic tissues from the two groups of mice by electron microscopy, which showed an overall healthier morphology of mitochondria in the livers of NEN-treated mice, characterized by a round or oval shape with clear intraorganelle structure compared to the prolonged, deformed tubular structures observed in the control mice (Supplementary Fig. 5a ). There was no apparent difference in hepatic mitochondria content between the two groups under electron microscopy ( Supplementary Fig. 5a ), which we confirmed by real-time PCR quantification of mitochondrial DNA (Supplementary Fig. 5b) . Consistently, expression of the transcription factor peroxisome proliferator-activated receptor γ coactivator 1-α (Pgc1-α), which regulates mitochondria biogenesis, did not seem to differ between the two groups ( Supplementary Fig. 5c ).
Hyperinsulinemic-euglycemic clamp studies of NEN effects
We performed hyperinsulinemic-euglycemic clamp studies on C57BL/ 6J mice fed either HFD or HFD containing NEN for 2 months. These studies confirmed the higher insulin sensitivity of the NEN-treated mice, as reflected by a more than 50% higher clamped glucose infusion rate required to maintain a similar euglycemic state ( Table 1) . The higher insulin sensitivity in these mice was associated with better hepatic insulin action, higher glucose turnover rates and marginally lower clamped hepatic glucose production compared to the control mice ( Table 1) . Moreover, the NEN-treated mice exhibited higher glycogen synthesis rates compared to controls ( Table 1) , which was further confirmed by direct measurement of glycogen synthesis in the liver and muscle (data not shown). The NEN-treated mice also contained less fat mass than controls (Supplementary Table 1a) , although glucose uptake by fat did not appear to contribute directly to the improvement in insulin action (data not shown).
In addition, the clamp studies showed that whole-body glycolysis rate and basal hepatic glucose production did not differ significantly between the two groups of mice (P = 0.8; Table 1 ). This finding was consistent with analyses of glucogenogenesis enzymes, which showed no significant changes in the expression of phosphoenolpyruvate carboxykinase and glucose-6-phosphatase and only slightly lower expression of pyruvate carboxylase in the NEN-treated mice compared to controls (Supplementary Fig. 6 ).
The effect of NEN on cellular metabolism
The in vivo results support the hypothesis that NEN sensitizes the insulin response through uncoupling of hepatic mitochondria, increasing hepatic lipid oxidation and consequently reducing lipid accumulation in the liver and probably other tissues. To examine the molecular mechanism by which NEN promotes lipid oxidation, we first characterized the effect of NEN on cellular metabolism in (Fig. 5a) . Moreover, NEN activated AMPK in a dose-and timedependent manner (Fig. 5b) that correlated with its mitochondrial uncoupling activity (Supplementary Fig. 1 ). In addition, NEN led to an increase in acetyl-CoA carboxylase (ACC) phosphorylation, which was dependent at least partially on AMPK activity, as treatment with an AMPK inhibitor, Compound C 52,53 , diminished ACC phosphorylation (Fig. 5c) . In human liver carcinoma HepG2 cells, NEN increased fatty acid oxidation by fivefold, which was accompanied by an activation of AMPK and an increase in phosphorylated ACC levels (Fig. 5d) . These results support that in cultured cells, NEN can increase lipid oxidation through activating AMPK, which phosphorylates and inhibits ACC, an inhibitor of mitochondrial β-oxidation. We then analyzed the hepatic AMPK-ACC pathway in vivo. Both short-term (overnight) and chronic (weeks) oral NEN treatment increased the levels of phosphorylated AMPK (Fig. 5e) . In addition, chronic NEN treatment led to lower total ACC (tACC) protein expression ( Fig. 5f ) and a higher ratio of phosphorylated ACC (pACC) to tACC (Fig. 5f) . We analyzed AMPK and ACC phosphorylation in other tissues, including muscles and adipose, and found no change (data not shown). These results again support that the liver is a direct target of NEN and that the hepatic AMPK-ACC pathway contributes to the effect of NEN on promoting lipid oxidation in vivo.
Previous studies have shown that niclosamide can also inhibit the Wnt 54, 55 or Stat3 (ref. 56 ) pathway in cultured cell models. We tested whether oral NEN affects the Wnt or Stat3 pathway in vivo at our dosage. Direct analyses of the pathways, as well as their downstream events, in mouse liver samples showed no difference between the mice fed with or without NEN (Supplementary Fig. 7) , indicating that the two pathways do not contribute to the antidiabetic effect of NEN. As an additional demonstration of the importance of mitochondrial uncoupling activity, we made a NEN derivative ( Supplementary  Fig. 7f ) that contains a sulfonate conjugation at the 2-hydroxyl site, which is a group essential for mitochondrial uncoupling 25 . The compound lost mitochondrial uncoupling activity ( Supplementary  Fig. 7g ) and did not show any antihyperglycemic activity in vivo (data not shown).
DISCUSSION
Niclosamide (the free base form) is an FDA-approved anthelmintic drug whose mechanism of action is to uncouple parasitic mitochondria. We tested the effect of NEN, the ethanolamine salt form of niclosamide, on hepatic lipid accumulation and hyperglycemic conditions in mice. Our results demonstrate that NEN uncouples mammalian mitochondria with modest potency (it is effective at high nanomolar concentrations). When administrated orally to mice, NEN is distributed primarily to the liver and has a short half-life. Oral NEN increases energy expenditure and lipid oxidation, markedly improves hepatic steatosis and is efficacious in preventing and treating diabetic symptoms that develop during HFD-induced obesity in mice. Moreover, NEN is effective in treating hyperglycemia in db/db mice, slows down the progression of the disease and reduces glycated HbA1c levels by over 2%. This study together with a previous study 41 demonstrate that the beneficial effects of promoting mitochondrial uncoupling in the liver to increase hepatic fat oxidation can be dissociated from potential toxicities and support this approach for treating hepatic steatosis, insulin resistance and obesity-related T2D.
At the tissue and organ levels, our results from the pharmacokinetic studies, tissue distribution studies and histological and biochemical analyses, as well as those from the clamp studies, support the notion that the liver is a primary target of NEN. Our results are consistent with the model that NEN improves insulin sensitivity through its direct action of mitochondrial uncoupling in the liver and the consequent reduction of hepatic lipid accumulation, as well as through its secondary effects on muscle and adipose. Correlated with lower hepatic lipid accumulation, the liver tissues of NEN-treated mice showed lower cytosolic DAG levels and an overall healthier mitochondrial morphology. However, these mice showed little change in the expression of proinflammatory cytokines such as those encoded by Tnfa and Il6 in liver or adipose tissue. These data support the hypothesis that the improvement in glycemic control by NEN treatment may result from altered mitochondrial function and subsequent reduction in hepatic lipid loads, as well as in specific lipid metabolites such as DAG, rather than an effect on inflammation.
The exact molecular mechanism underlying the upregulation of hepatic lipid oxidation by mitochondrial uncoupling might be complex. We observed that NEN reduces intracellular ATP concentrations, increases the ADP-to-ATP ratio (which is indicative of an increase in AMP levels), activates AMPK and increases ACC phosphorylation in cells. Likewise, NEN treatment activates AMPK and increases ACC phosphorylation (resulting in inhibition of ACC activity) in mouse livers. Thus, it is probable that the AMPK-ACC pathway is involved in the upregulation of lipid oxidation triggered by mitochondrial uncoupling. Activation of AMPK through inhibiting complex I is one of the mechanisms proposed for the antidiabetic action of metformin 57 (although the contribution of this mechanism at clinically relevant dosages remains debatable 58 ), which is associated with an increased risk of lactic acidosis 53 . In contrast, NEN increases mitochondrial oxidation and is expected to be less likely to associate with the development of lactic acidosis, which is exemplified by the reduction in plasma lactate levels in NEN-treated mice.
Niclosamide and NEN have known toxicity profiles. In humans, the oral therapeutic dosage of niclosamide is 2,000 mg day −1 (or about 25 mg kg −1 day −1 ) in adults and 1,000-1,500 mg day −1 in children. Despite its higher water solubility, the LD 50 of oral NEN in mammals appears to be the same or even higher than that of niclosamide (the LD 50 of NEN in rats is 10,000 mg kg −1 body weight) 45, 46, 59 . Long-term toxicology studies (over 300 days) of oral treatment show that the dosage of NEN with nonadverse effects in rats is over 25,000 p.p.m. in feed 45, 46, 59 , which is about one order of magnitude higher than the dosage we used. It is not totally clear why oral NEN has an excellent safety profile over a wide concentration range, whereas oral DNP has a relatively narrow therapeutic index. We suspect that the answer lies in the difference in pharmacokinetic properties between NEN and DNP. The peak levels of DNP after ingestion correlate well with toxicity 41 , whereas NEN is rapidly metabolized by the liver, with a half-life of about 1.5 h and no accumulation in the body after several hours. In addition, NEN is relatively poorly soluble in water 45 , which could effectively limit its maximal absorption rate. This property would serve as an additional fail-safe mechanism against possible accumulation of NEN associated with overdose. Moreover, NEN is mostly albumin bound in plasma 60 , which limits the extraction of NEN to tissues other than the liver. In particular, existing toxicology studies have not indicated that either niclosamide or NEN increases body temperature 45, 46, 59 . This finding is consistent with our results that despite the fact that NEN increases energy expenditure, it does not increase body temperature. This outcome is probably due to the mild nature of mitochondrial uncoupling induced by NEN after oral administration and the robustness of body temperature homeostatic regulation in mice.
In summary, we provide evidence that NEN, a salt form of the FDA-approved drug niclosamide, has excellent antidiabetic effects. NEN represents a new class of antidiabetic compounds with a new mechanism of action associated with a number of appealing features. For example, it may provide a cure to hepatic insulin resistance, as it improves hepatic steatosis and corrects the underlying etiologic factor in such resistance while not increasing the risk of lactic acidosis. In addition, NEN itself has a well-documented safety profile in mammalian animals. Thus, this study opens the possibility of further developing NEN and other safe mitochondrial uncouplers for treating metabolic diseases.
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Glycated hemoglobin A1c levels in db/db mice (n = 9) were determined at the US National Mouse Metabolic Phenotyping Center (MMPC) at University of California, Davis (UC Davis). Blood samples were collected from the tail veins of mice that had been fed with normal diet or normal diet containing 1,500 p.p.m. NEN for 60 d.
Measurement of hepatic triglyceride.
For the quantification of hepatic triglyceride content, 0.2-0.3 g of freshly dissected mouse liver tissue was homogenized with 1 ml saline solution, and then total triglyceride was extracted with 20 ml solvent (chloroform and methanol, 2:1 (v/v)). The homogenized suspensions were then filtered through Whatman filter paper, and 10 ml of clean solution was transferred to a clean vial and air dried. The remained triglycerides were then dissolved in 5 ml solvent containing 60% butanol and 40% of a Triton X-114 and methanol mix (2:1 (v/v)). Final triglyceride contents were determined using the triglyceride determination kit (Sigma) and normalized to the tissue weight.
Mouse liver histological analysis. For liver histological studies, mice were euthanized by decapitation, and liver tissues were fixed with neutral buffered formalin 10% (Surgipath Medical Industries, Inc.) and embedded in paraffin. Tissue sections were prepared and stained with H&E. For the Oil Red O staining, liver tissues were prepared as frozen sections. Images were acquired with a Universal Microscope Axioplan 2 imaging system (Carl Zeiss) with phase-contrast objectives.
Electron microscopy. Electron microscopy study of the liver tissues was performed in collaboration with the Rutgers University electron microscopy core facility 64 . C57BL/6J mice were fed with HFD or HFD containing 1,500 p.p.m. NEN for 8 weeks (n = 3). The liver tissues were then dissected and fixed with 2.5% gluteraldehyde and 4% paraformaldehyde in 0.1 M cacodylate buffer. Thin sections (90 nm) of each sample were prepared on a Reichert Ultracut E microtome. Sections were viewed with a JEOL 1200EX transmission electron microscope.
Metabolic cage studies. Metabolic cage studies were performed at MMPC at Case Western Reserve University. C57BL/6J mice were fed with HFD or HFD containing 1,500 p.p.m. NEN for 1 week (n = 8). The oxygen consumption, carbon dioxide generation, energy expenditure and respiration quotients of the mice were determined by IDC 65 using the Oxymax system (Columbus Instruments' Comprehensive Lab Animal Monitoring System, Columbus, OH). Experiments were performed on mice in the presence of food. The data were collected every 18 min on each mouse, and collection continued for more than 24 h (including a 12-h light phase and a 12-h dark phase). The results are reported in 90-min intervals (each point represents an average of five 18-min intervals). Body temperatures of the mice were measured by rectal probe.
Pharmacokinetic studies. Pharmacokinetic analyses of oral NEN in mice were performed by BioDuro Inc. using methods described previously 66 . Briefly, NEN was dissolved in 0.5% methyl cellulose and given to male C57BL/6J mice (n = 3) at 6 weeks of age by gavage at a dose of 40 mg per kg body weight, and blood samples were collected at the indicated time points. 10 µl plasma was mixed with 2 µl methanol and 200 µl of 200 ng ml −1 internal standard diclofenac in acetonitrile and kept at -20 °C for 30 min, and 10 µl of the supernatant after vortexing and centrifuging was subjected to liquid chromatography-tandem mass spectrometry (LC/MS/MS) analyses. For tissue distribution studies, NEN was administered to mice (n = 3 for each time point) by gavage at a dose of 40 mg per kg body weight. Mice were then euthanized at the 2, 4, 8 or 24 h time points. 100 mg of each tissue was homogenized with 5× volume of water (500 µl), and then 50 µl of the homogenate was mixed with 5 µl methanol and 300 µl of 200 ng ml −1 internal standard diclofenac in acetonitrile, kept at -20 °C for 30 min and then vortexed for 1 min and centrifuged at 12,000g for 15 min. 10 µl of supernatant was subjected to LC/MS/MS analyses.
Hyperinsulinemic-euglycemic clamp studies. The hyperinsulinemic-euglycemic clamp studies were performed at MMPC at the University of Massachusetts as described previously 67 . Briefly, C57BL/6J mice (n = 14) were fed with HFD or HFD containing 1,500 p.p.m. NEN for 8 weeks before the clamp studies. After an overnight fast, mice were subjected to a 2-h hyperinsulinemic-euglycemic clamp with a primed-continuous infusion of human insulin at a rate of 2.5 mU per kg body weight per min to raise plasma insulin levels to within a physiological range. 20% glucose was infused at variable rates to maintain plasma glucose at basal concentrations. All infusions were performed using microdialysis pumps. Insulin-stimulated whole-body glucose turnover was estimated with a continuous infusion of At the end of the clamps, mice were anesthetized with sodium pentobarbital injection. Within 5 min, three muscles (gastrocnemius, tibialis anterior and quadriceps) from both hindlimbs, epididymal white adipose tissue and liver were collected for biochemical analyses. 11 mice per group with a complete set of data were included and analyzed. Student's t test was used to determine statistical significance between the control and NEN-treated mouse groups.
DAG and ceramide assays. Intrahepatic DAG and ceramide analyses were performed as described previously 68 . C57BL/6J mice (n = 8) were fed with HFD or HFD containing 1,500 p.p.m. NEN for 8 weeks, then liver tissues were dissected and frozen in liquid nitrogen immediately. For DAG and ceramide extraction, liver tissues were homogenized in a buffer solution (20 mM Tris-HCl, 1 mM EDTA, 0.25 mM EGTA, 250 mM sucrose and 2 mM PMSF) containing a protease inhibitor mixture, and samples were centrifuged at 100,000g for 1 h. The supernatants containing the cytosolic fraction and the pellet containing the plasma membrane were collected as described previously 68 . Both the cytosolic and membrane contents of DAGs and ceramides were measured by LC/MS/MS. The contents of DAGs and ceramides are expressed as the sum of the individual species including DAGs (C16:1, C16:0, C18:2, C18:1 and C18:0) and ceramides (C16:0, C18:0, C20:0, C22:0, C24:1 C24:0). All measurements were performed in animals under basal conditions after a 6-h fast.
Quantitative real-time PCR assays. For quantitative real-time PCR analyses, total RNA was extracted from mouse livers or white adipose tissue lysates using TRIzol reagent (Invitrogen, Carlsbad, CA) and standard protocol. 5-20 ng of total RNA from each sample was then used to generate high-fidelity cDNA for quantitative PCR analyses. The cDNA was amplified using the AffinityScript QPCR cDNA Synthesis Kit (Agilent Technologies, Santa Clara, CA). For the mitochondrial cytochrome c oxidase subunit II gene (Coxii), DNA was prepared and analyzed. The following primers were used for the TaqMan real-time PCR assays: phosphoenolpyruvate carboxykinase (Pepck): forward, 5′-AGCGGATATGGTGGGAAC-3′; reverse, 5′-GGTCTCCACTCCTTGTTC-3′; glucose-6-phosphatase (G6pc): forward, 5′-AAAGAGACTGTGGGCATCAATC-3′; reverse, 5′-AATGCCTGACAAGACTCCAGCC-3′; E-cadherin: forward, 5′-ACTGTGAAGGGACGGTCAAC-3′; reverse, 5′-GGAGCAGCAGGATCAGAATC-3′; tumor necrosis factor-α alpha (Tnfa): forward, 5′-GGCAGGTCTACTTTGG AGTCATTGC-3′; reverse, 5′-ACATTCGAGGCTCCAGTGAATTCGG-3′; interleukin-6 (Il6): forward, 5′-GAGGATACCACTCCCAACAGACC-3′; reverse, 5′-AAGTGCATCATCGTTGTTCATACA-3′; cytochrome c oxidase subunit II (Coxii): forward, 5′-CTGAAGACGTCCTCCACTCA-3′; reverse, 5′-TCAGAGCATTGGCCATAGAA-3′.
TaqMan real-time PCR was done in triplicate with the TaqMan PCR mixture (Applied Biosystems). The relative expression levels of each gene were normalized against the expression of Gapdh.
Statistical analyses. One-way ANOVA was used for the statistical analyses in the IDC studies. Student's t test was used for the statistical analyses in all other studies. Data are presented as the means ± s.d., and statistical significance is denoted as *P < 0.05, **P < 0.01 and ***P < 0.001. 
